Novo Nordisk

Novo NordiskNovo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries.

Novo Nordisk RSS Channel

Display # 
Title Published Date
International study prompts rethink on the rise of diabetes in cities 16 November 2015
Novo Nordisk and University of Washington to collaborate on exploring the role of the brain in regulating blood glucose and obesity 03 November 2015
Novo Nordisk and MIT to collaborate on researching the next generation of drug delivery devices 07 September 2015
Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark 27 August 2015
United States first country to launch Saxenda® 22 April 2015
Novo Nordisk opens new insulin formulation and filling facility in Russia 10 April 2015
Novo Nordisk second best in the world at providing access to medicine 17 November 2014
Novo Nordisk second best science employer in the world 17 October 2014
Novo Nordisk establishes new obesity research unit in Seattle 26 September 2014
Novo Nordisk launches 'Cities Changing Diabetes' to fight urban diabetes 28 March 2014

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]